Optimal duration and effectiveness of neoadjuvant endocrine therapy in breast cancer - Retrospective series

A. Konsoulova-Kirova,J. Ribeiro, H. Gouveia,S. R. Volovat,B. Sousa, R. Marques,M. J. Brito,D. Pinto,P. Gouveia,M. A. Vasconcelos,E. Batista,M. J. Cardoso,C. Alves,F. Cardoso

EUROPEAN JOURNAL OF CANCER（2020）

引用 0|浏览9

暂无评分

摘要

Background: Neoadjuvant endocrine therapy (NAET) is increasingly used in ER+/Her2− breast cancer (BC). Its optimal duration as per current guidelines is 4–8 months or until maximal response. We studied efficacy outcomes and relationship between US assessed response and proliferative response/Ki67 dynamics. We analysed 2 cohorts of pts according to NAET goal: A) for tumor downsizing and B) frail or refusing other therapies.

查看译文

关键词

neoadjuvant endocrine therapy,breast cancer,optimal duration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要